Empire Genomics Licenses Biomarker from Cornell to Develop Prostate Cancer Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Empire Genomics today announced it has licensed a genomic biomarker from Cornell University for the development of a test to diagnose and determine treatment of patients with neuroendocrine prostate cancer, or NEPC.

Empire and Cornell will partner on developing a commercial grade assay and Empire plans to launch the NEPC test later this year. Empire also plans to seek a pharmaceutical partner to use the assay to accelerate patient stratification in clinical trials, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.